IKT vs JNPR · $215.2M cap vs P/E 38, $13.36B cap
Inhibikase Therapeutics Inc (IKT) versus Juniper Networks Inc (JNPR) — a side-by-side from cached financials, not a winner call.
Inhibikase Therapeutics Inc (IKT) is a biotechnology company listed on US.
Juniper Networks Inc (JNPR) is a communication equipment company listed on US.
Latest reported IKT revenue for 2026-06-30 was $0. Net income was -$36.0M. IKT currently screens at market cap $215.2M.
JNPR does not have a complete income-statement cache yet.
IKT currently screens at market cap $215.2M. JNPR currently screens at market cap $13.36B and trailing P/E 38.0.
Not investment advice. Open the IKT and JNPR stock pages for the full models.
Not investment advice.